Y mAbs Therapeutics

Y mAbs Therapeutics — Technical Presentation (May 2025)

49 slides from Y mAbs Therapeutics's technical presentation, May 28, 2025

  1. Slide 1: Radiopharmaceutical R&D Update May 28, 2025

    Radiopharmaceutical R&D Update May 28, 2025

  2. Slide 2: Disclaimer: Forward-Looking Statements

    Disclaimer Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the US Private Securities Litigation Reform Act of 1995 . The forward - looking statements involve substantial risks and uncertainties . All statements, other than statements of hist

  3. Slide 3: Today's Presenters

    Today’s Presenters Mike Rossi President and Chief Executive Officer Natalie Tucker SVP, Radiopharmaceutical Business Unit Head Norman LaFrance, MD Chief Medical and Development Officer 3 Additional Team Members Available During Q&A

  4. Slide 4: Y-mAbs is a Commercial Biopharmaceutical Company with Two Business Units

    Y - mAbs is a Commercial Biopharmaceutical Company with Two Distinct Business Units: DANYELZA and Radiopharmaceuticals 4 DANYELZA RADIOPHARMACEUTICALS

  5. Slide 5: Our Vision for Growth

    Our VISION for GROWTH 5 Deliver on Promise of Radiopharmaceuticals with Minimal O ff - Target E ffects Fully Operational Theranostic Platform Proprietary Radiohaptens Enabling Multiple Isotope Modularity Investment Favors Development, NOT CAPEX Physician Participation Along the Treatment Journey

  6. Slide 6: Positioned to Potentially Disrupt the Existing Approach to Radiopharmaceuticals

    We are Positioned to Potentially Disrupt the Existing Approach to Radiopharmaceuticals by Addressing Key Obstacles that Limit Commercial Utilization Leverage Existing Infrastructure • Assembly occurs in vivo • Reduced COGS and overhead Patient - Centric Targeting • Modular design enables isotope fle

  7. Slide 7: Multiple Potential High Value Inflection Points Anticipated Ahead

    7 Radiopharmaceuticals: Multiple Potential High Value Inflection Points Anticipated Ahead Increasing commitment, capabilities, and leadership in Radiopharmaceuticals 2025 2026 2027 Realignment into two business units: DANYELZA and Radiopharmaceuticals CD38 - SADA FPI in 1H 2025 GD2 - SADA Trial 1001

  8. Slide 8: Today's Agenda: Three Key Radiopharmaceutical Updates

    8 Today’s Agenda: Three Key Radiopharmaceutical Updates 1. Trial 1001 Part A – Complete 2. Key Learnings from Molecule Optimization Studies 3. Expanded Development Pipeline Y - mAbs Development

  9. Slide 9: Recent Insights Will Be Scaled Across the Platform

    9 Recent Insights Will Be Scaled Across the Platform 1 Met primary objective demonstrating GD2 - SADA - 177 Lu - DOTA is safe and well tolerated 2 GD2 - SADA PK was predicted and with close interpatient cohort repeatability 3 Identified opportunities to streamline study designs and improve operation

  10. Slide 10: Today's Agenda: Three Key Radiopharmaceutical Updates

    10 Today’s Agenda: Three Key Radiopharmaceutical Updates 1. Trial 1001 Part A – Complete 2. Key Learnings from Molecule Optimization Studies 3. Expanded Development Pipeline Y - mAbs Development

  11. Slide 11: Trial 1001 Phase 1 Clinical Trial Background

    GD2 - SADA Trial 1001 Phase 1 Clinical Trial Background 11

  12. Slide 12: Phase 1 Trial 1001, Part A: Study Objectives and Design

    12 Cohort 6 Cohort 5 Cohort 4 Cohort 3 Cohort 2 Cohort 1 1 mg/kg 1 mg/kg 3 mg/kg 1 mg/kg 0.3 mg/kg 0.3 mg/kg GD2 - SADA 3 4 5 5 2 5 Interval (days) • Primary : Establish safety of GD2 - SADA • Secondary : Evaluate dosimetry, PK, and immunogenicity profiles of GD2 - SADA - 177 Lu - DOTA • HR - NB (≥1

  13. Slide 13: Part A Treatment Regimen: Imaging Stage and Treatment Stage

    13 Part A Treatment Regimen Was Based on Tumors Selected by CT and Included an Imaging Stage Followed by a Treatment Stage Day 1 GD2 - SADA Protein 0.3, 1.0, or 3.0 mg/kg Day 3+ 177 Lu - DOTA 30 mCi Nuclear Imaging Determination of tumor uptake (in 5 prev. selected) Blood was collected at serial tim

  14. Slide 14: Patient Demographics

    Patient Demographics 14

  15. Slide 15: Patients Treated with the Complex: Enrollment Flow

    15 A Total of 22 Patients Were Treated with the GD2 - SADA - 177 Lu - DOTA Complex Patients screened 31 Screen failures ( i. e., no measurable disease, lab values out of inclusion and serious intercurrent illness) 8 Withdrawal from study post Grade 3 AE after first GD2 - SADA protein dose 1 No tumor

  16. Slide 16: Patients Were Heavily Pretreated and Similarly Distributed Across Cohorts

    16 Patients Were Heavily Pretreated and Similarly Distributed Across Cohorts Program: t_demog.sas - output: t_demog.rtf - executed: 24APR2025 – data cutoff 22APR2025 N: Number of patients, BMI: Body mass index, ECOG: Eastern Cooperative Oncology Group Performance Status Scale, SCLC: Small - Cell Lun

  17. Slide 17: Patients in Imaging Stage Showed Positive Tumor Uptake

    17 9 Patients in the Imaging Stage Showed Positive Tumor Uptake Per Protocol Design and Were Eligible for Treatment Stage Overview of patients who showed tumor uptake Cohort 6 (3 - day interval) Cohort 6 (3 - day interval) Cohort 6 (3 - day interval) Cohorts 5 (4 - day interval) Cohort 4 (5 - day in

  18. Slide 18: Safety Summary

    Safety Summary 18

  19. Slide 19: Safety Summary: Part A Safe and Well-Tolerated

    19 Safety Summary : Part A was Safe and Well - Tolerated Across Both GD2 - SADA and 177 Lu - DOTA Administrations • No AE trends across all dosing cohorts • No DLTs or treatment - related serious adverse events • Treatment related adverse events were mostly CTCAE grade 1 (70%) and 2 (27.5%) • ADA di

  20. Slide 20: Manageable Safety Profile: No DLTs, No Treatment-Related SAEs

    20 Manageable Safety Profile: No DLTs, No Treatment - related SAEs 0 3 8 16 123 128 0 1 0 1 40 40 0 20 40 60 80 100 120 140 DLT AESI SAE Grade 3+ Any TEAE Any AE Number of Events Adverse Event Type Related AE All AE TEAE: Treatment - emergent adverse event Grade 3+: Common terminology criteria for a

  21. Slide 21: Nausea, Chills Were the Most Common Related Adverse Events

    21 Nausea, Chills Were the Most Common Related Adverse Events 0 1 2 3 4 5 6 7 8 9 10 Nausea Lymphocyte count decreased Constipation Abdominal pain Arthralgia Back pain Chills Hypoalbuminaemia Hyponatraemia Pain in extremity Decreased appetite Fatigue TEAEs with a total frequency ≥ 10% N E 2 2 2 2 2

  22. Slide 22: No Dose-Dependent AE Trends; AESI Were Non-Serious

    22 No Dose - Dependent AE Trends as Seen With GD2 Therapies or Radiopharmaceuticals; AESI Were Non - Serious Patient 1, AESI 1: Abdominal Pain 3 Adverse Events of Special Interest (AESI) in 2 Patients Patient 2, AESIs 2 & 3: Liver Function 5: 1 mg/kg, 4 - day interval Cohort # Hx of elevated liver e

  23. Slide 23: Pharmacokinetics (PK)

    GD2 - SADA Pharmacokinetics (PK) 23

  24. Slide 24: Pharmacokinetics Outline the Optimal Clearance Interval

    24 Pharmacokinetics of GD2 - SADA Outline the Optimal Clearance Interval for Maximum Tumor - to - Kidney Ratio • Allometric scaling was used to model human GD2 - SADA PK based on preclinical data • GD2 - SADA blood trough was identified preclinically , i.e., lowest amount of GD2 - SADA in blood prio

  25. Slide 25: Pharmacokinetics are Dose Dependent and Predictably Follow Modeling

    25 GD2 - SADA Pharmacokinetics are Dose Dependent and Predictably Follow Modeling Source: Trial: Y - mAbs 1001 DMC. 06May2025 Note: Serum levels of GD2 - SADA were measured over time N=22: One patient who withdrew prior to 177 Lu - DOTA administration did not continue with PK sampling • The initial

  26. Slide 26: Dose Normalized PK Displayed Proportional Cmax and Clearance Rates

    26 Dose Normalized GD2 - SADA PK Displayed Proportional Cmax and Clearance Rates over Three Administered Dose Concentrations Source: Trial: Y - mAbs 1001. f_median_sada.rtf - 05May2025 Note: Serum levels of GD2 - SADA were measured over time, normalized by mg/kg of GD2 - SADA protein Time (hours) GD

  27. Slide 27: Lu-DOTA Pharmacokinetics (PK)

    177 Lu - DOTA Pharmacokinetics (PK) 27

  28. Slide 28: Lu-DOTA PK is a Function of Protein Concentration and Clearance Interval

    177 Lu - DOTA PK is a Function of the GD2 - SADA Protein Concentration and Clearance Interval Allowing the Optimization of Therapeutic Index 28 Note: Pre - dose GD2 - SADA concentration is assigned a value of 10, as it is 0 ng/mL for all included records • Higher concentrations of GD2 - SADA in seru

  29. Slide 29: Lu-DOTA PK by Cohort Illustrates Dual Impact of Concentration and Interval

    177 Lu - DOTA PK by Cohort Illustrates Dual Impact of GD2 - SADA Concentration and Clearance Interval 29 Note: Pre - dose GD2 - SADA concentration is assigned a value of 10, as it is 0 ng/mL for all included records 177 Lu - DOTA PK by Cohort (safety analysis set) 177 Lu - DOTA • Multiple protein do

  30. Slide 30: Lu-DOTA Dosimetry

    GD2 - SADA - 177 Lu - DOTA Dosimetry 30

  31. Slide 31: Tumor Uptake Restricted to Site Selected Target Lesions; Expanded Evaluation

    31 Per Protocol, Tumor Uptake Was Restricted to Site Selected Target Lesions Identified via CT; Expanded Evaluation Included All Tumors OLINDA/EXM 2.2 (Organ Level INternal Dose Assessment/ EXponential Modeling), Hermes Medical Solutions Expanded Evaluation Per Protocol Evaluation Next generation im

  32. Slide 32: Per Protocol Evaluation: Patients with Tumor Uptake

    32 Per Protocol Evaluation: 9 of 22 Patients Were Identified as Having Tumor Uptake Patient 021 Patient 019 Patient 018 Patient 016 Patient 011 Patient 009 Patient 008 Patient 005 Patient 003 6 6 6 5 4 3 3 3 2 Cohort 1.0 1.0 1.0 1.0 3.0 1.0 1.0 1.0 0.3 GD2 - SADA protein dose (mg/kg) 3 3 3 4 5 5 5 5

  33. Slide 33: Per Expanded Evaluation: 16 of 22 Patients Showed Tumor Uptake

    33 Note: All data based on 30mCi 177 LuDOTA diagnostic dose; Gy represents absorbed dose; column colors represents cohorts Patient 21 (pending analysis ): positive tumor uptake confirmed, dosimetry calculations on hold pending receipt of additional imaging data (CT scan ) Patient 22 (pending analysi

  34. Slide 34: Per Expanded Evaluation: Patients Showed Tumor Uptake, Increased Gray per Tumor

    34 Per Expanded Evaluation : 16 of 22 Patients Showed Tumor Uptake, Largely Presenting with Increased Gray per Tumor Patient 022 Patient 017 Patient 015 Patient 014 Patient 013 Patient 006 Patient 004 Patient 021 Patient 019 Patient 018 Patient 016 Patient 011 Patient 009 Patient 008 Patient 005 Pat

  35. Slide 35: Protocol Artificially Restrained Tumor Selection

    35 Protocol Artificially Restrained Tumor Selection and Resulted in Additional Tumors with Dose Uptake Excluded from Evaluation Positive Patient: Nontarget Lesion with Uptake Patient ### - ## - #### - 011: Cohort 5, 1 mg/kg GD2 - SADA + 3 - day clearance interval, Uveal Melanoma Patient continued on

  36. Slide 36: Implication to Platform: 1001 Part A Key Learning

    36 Implication to Platform 1001 Part A – Key Learning Accelerate trial with parallel cohorts, single variable modifications; leverage protein PK to determine dosing interval FiH demonstration of SADA shown to be safe and well tolerated with predictable PK* 1 Utilize central review of Nuclear Images

  37. Slide 37: Today's Agenda: Three Key Radiopharmaceutical Updates

    37 Today’s Agenda: Three Key Radiopharmaceutical Updates 1. Trial 1001 Part A – Complete 2. Key Learnings from Molecule Optimization Studies 3. Expanded Development Pipeline Y - mAbs Development

  38. Slide 38: Two Studies in Q1 2025 to Identify Opportunities to Improve Tumor Uptake

    38 Two Studies Were Conducted in Q1 2025 to Evaluate GD2 - SADA Complex and Identify Opportunities to Improve Tumor Uptake Current Molecule Improved Molecule Y - mAbs 20 pmole (DOTA) Current Molecule Improved Molecule TUMOR KIDNEY Y - mAbs 20 pmole (DOTA) Current Molecule Improved Molecule TUMOR Y -

  39. Slide 39: Improved Molecule Will Consist of a New Radiohapten and Modified Specific Activity

    39 Improved Molecule W ill C onsist of a New Radiohapten and Modified S pecific A ctivity No Change Necessary Change to New Proprietary Radiohapten Change to low Specific Activity (SA) / High Mass No change enables use of existing manufactured protein x Formulation 177 Lu - DOTA Protein Improved tum

  40. Slide 40: New Radiohapten Expands Access to a Range of Isotopes

    40 New Radiohapten Expands Access to a Range of Isotopes with Theranostic Applications, Including Alphas and PET Proprietary R adiohapten creates a “universal linker” to accommodate all payloads with picomolar affinity to anti - DOTA in SADA BsAB (with rapid clearance into the urine) NEW - Proprieta

  41. Slide 41: Improved Molecule Incorporated into a Bridge Study in 1H 2026

    The Improved Molecule Will be Incorporated into a Bridge Study in 1H 2026 * Through a Proposed Amendment ** to the Current IND 1H 2026 – 2H 2026 * • Confirm safety of new Radiohapten in humans • Assess impact of Radiohapten and mass dose on therapeutic index • Optimize clearance intervals (longer re

  42. Slide 42: Today's Agenda: Three Key Radiopharmaceutical Updates

    42 Today’s Agenda: Three Key Radiopharmaceutical Updates 1. Trial 1001 Part A – Complete 2. Key Learnings from Molecule Optimization Studies 3. Expanded Development Pipeline Y - mAbs Development

  43. Slide 43: Systemic Evaluation to Identify Optimal Targets for the Platform

    43 We Conducted a Systemic Evaluation to Identify Optimal Targets for the Y - mAbs Platform and Narrowed Selection in 3 Phases 15 Prioritized Targets Staged over Few Years Broad Target Universe Initial refinement – Cancer types of interest (24 cancer types) Second refinement – Tumor Refinement (675

  44. Slide 44: Targets Phased Across Years, Focused on Three Franchises

    44 The Targets Were Phased Across 3 Years, with the Early Years Focused on Derisking the Innovative Platform …and strategic diversification of pipeline expansion Gastrointestinal Lung Women’s Cancers Targets are Focused on Three Franchise Opportunities 2027 2026 2025 e.g. SCLC, NSCLC, TNBC, Ovarian,

  45. Slide 45: Our Radiopharmaceutical Pipeline

    45 Our Radiopharmaceutical Pipeline THERAPEUTIC PIPELINE Phase 2 Phase 1 Preclinical R&D Isotope Asset 177 Lu GD2 - SADA - 177 Lu - Proteus R/R SCLC, Sarcoma, Malignant Melanoma, HR Neuroblastoma GD2 177 Lu CD38 - SADA R/R Non - Hodgkin Lymphoma CD38 Ac225 Antibody Colorectal Cancer Undisclosed Alph

  46. Slide 46: Multiple Potential High Value Inflection Points Anticipated Ahead

    46 Radiopharmaceuticals: Multiple Potential High Value Inflection Points Anticipated Ahead Increasing commitment, capabilities, and leadership in Radiopharmaceuticals 2025 2026 2027 Realignment into two business units: DANYELZA and Radiopharmaceuticals CD38 - SADA FPI in 1H 2025 GD2 - SADA Trial 100

  47. Slide 47: In Conclusion: Recent Insights Will Be Scaled Across the Platform

    47 In Conclusion: Recent Insights Will Be Scaled Across the Platform GD2 - SADA Protein is safe and well - tolerated Protein PK and dosing interval optimize the Therapeutic Index New Universal Radiohapten expected to modularize the platfor m, allow for multiple isotopes, and improve tumor retention

  48. Slide 48: Y-mAbs Therapeutics, Inc.

    Therapeu! itics, Inc.

  49. Slide 49: Thank You

    Thank You 49

Y-mAbs Therapeutics — Technical Presentation (May 2025) on 6ix